The 7,817 patients studied had a more serious type of heart attack that is typically caused by a blood clot completely blocking the coronary artery, leading to damage and the death of heart muscle. The treatment period was 24 months.
The SoC for STEMI treatment is an antiplatelet drug alone without an anticoagulant, so this is a pretty significant and surprising finding.
Paradoxically, Xarelto was recently rejected by the FDA as a treatment for ACS (#msg-76856261); it is still being considered such this indication in the EU.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.